Sudarshan Pharma Industries Limited has submitted an updated investor presentation to BSE Limited under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation provides comprehensive insights into the company's business operations, strategic initiatives, and financial performance.

Company Milestones and Strategic Development

The presentation outlines the company's evolution from 2008 to 2026, demonstrating consistent growth and expansion. Key developments include the establishment of manufacturing capabilities, market expansion across multiple states, and strategic acquisitions.

Recent Strategic Initiatives

The company has undertaken significant strategic initiatives in recent years, including major acquisitions and expansion plans.

Business Operations and Vertical Integration

The company focuses on vertical integration across the pharmaceutical value chain, spanning from R&D to branded generics. This strategy encompasses chemical raw materials for pharmaceuticals, intermediates for API, API manufacturing and import, finished formulation development, and branded generics production.

The business operates through multiple subsidiaries including wholly-owned entities Ratna Lifescience Private Limited and Life Science Chemical Private Limited, along with majority stakes in other pharmaceutical companies. The Hyderabad manufacturing unit specializes in bulk drug and intermediate manufacturing with approximately 50 potential API key starting materials.

Market Position and Client Base

The presentation highlights the company's extensive client portfolio, including major pharmaceutical companies such as Cipla, Biocon, Sun Pharma, Lupin, Zydus, and Takeda. The company has established export operations across multiple countries including the USA, Canada, UK, Netherlands, UAE, Australia, and various African markets.

Financial Performance Overview

The company has demonstrated consistent financial growth across key metrics. Revenue from operations increased from Rs. 463.54 Crores in FY24 to Rs. 505.05 Crores in FY25. EBITDA showed substantial improvement from Rs. 22.80 Crores in FY24 to Rs. 39.90 Crores in FY25, while PAT grew from Rs. 11.46 Crores to Rs. 15.88 Crores during the same period.

Leadership and Management

The presentation features the company's leadership team, including Chairman & Managing Director Mr. Hemal V. Mehta with 26 years of pharmaceutical industry experience, and Joint Managing Director & CFO Mr. Sachin V. Mehta. The board includes independent directors with extensive expertise in biotechnology, legal affairs, and pharmaceutical operations.

Sudarshan Pharma Industries Limited has announced a board meeting scheduled for January 28, 2026, to review and approve the company's quarterly financial performance. The pharmaceutical company informed BSE Limited about this development through an official communication dated January 22, 2026.

Board Meeting Details

The Board of Directors will convene on Wednesday, January 28, 2026, with the primary agenda being the consideration and approval of unaudited financial results for the quarter ended December 31, 2025. The meeting will cover both standalone and consolidated financial statements for the third quarter of FY26.

Regulatory Compliance

The announcement has been made pursuant to Regulation 29 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This regulation mandates listed companies to inform stock exchanges about board meetings where financial results will be considered, ensuring transparency and timely disclosure to investors and stakeholders.

Trading Window Restrictions

Sudarshan Pharma Industries has notified that the company's trading window will continue to remain closed until 48 hours after the declaration of the financial results for the quarter ended December 31, 2025. This measure is implemented to prevent insider trading and ensure fair market practices during the period when price-sensitive information is being processed and disclosed.

Company Information

Sudarshan Pharma Industries Limited operates from its head office located at 301, Aura Biplax, Premium Retail Premises, 7, S.V. Road, Borivali (West), Mumbai - 400092. The company is listed on BSE with scrip code 543828 and trades under the symbol SUDARSHAN. The official communication was signed by Nirav Shah, Company Secretary and Compliance Officer, emphasizing the company's commitment to regulatory compliance and transparent corporate governance practices.